Literature DB >> 27520997

Rivaroxaban in treatment refractory heparin-induced thrombocytopenia.

Joshua Misha Lewis Casan1, George Grigoriadis1, Noel Chan1, Sanjeev Chunilal1.   

Abstract

Following orthopaedic surgery, a 56-year-old woman developed heparin-induced thrombocytopenia (HIT), complicated by extensive proximal deep vein thrombosis. The patient did not respond to multiple conventional therapies; however, a prompt treatment response occurred after starting rivaroxaban at standard dosing. This case represents the first documentation of efficacy for rivaroxaban in the setting of treatment refractory HIT and strengthens the limited existing evidence for this agent in HIT. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27520997      PMCID： PMC4986039          DOI： 10.1136/bcr-2016-216110

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  8 in total

1.  Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.

Authors:  J Amiral; F Bridey; M Dreyfus; A M Vissoc; E Fressinaud; M Wolf; D Meyer
Journal:  Thromb Haemost       Date:  1992-07-06       Impact factor: 5.249

Review 2.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Rivaroxaban for treatment of heparin-induced thrombocytopenia after cardiac surgery: A case report.

Authors:  Laure Abouchakra; Ziad Khabbaz; Samah Abouassi; Georges Badaoui
Journal:  J Thorac Cardiovasc Surg       Date:  2015-05-08       Impact factor: 5.209

4.  Rivaroxaban for arterial thrombosis related to heparin-induced thrombocytopenia.

Authors:  Philippe Hantson; Catherine Lambert; Cédric Hermans
Journal:  Blood Coagul Fibrinolysis       Date:  2015-03       Impact factor: 1.276

5.  First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia.

Authors:  H J Ng; H Than; E C Y Teo
Journal:  Thromb Res       Date:  2014-06-14       Impact factor: 3.944

6.  Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia.

Authors:  Michelangelo Sartori; Elisabetta Favaretto; Michela Cini; Cristina Legnani; Benilde Cosmi
Journal:  J Thromb Thrombolysis       Date:  2015-10       Impact factor: 2.300

7.  Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.

Authors:  Jeanine M Walenga; Margaret Prechel; Walter P Jeske; Debra Hoppensteadt; Jyothi Maddineni; Omer Iqbal; Harry L Messmore; Mamdouh Bakhos
Journal:  Br J Haematol       Date:  2008-07-30       Impact factor: 6.998

8.  Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study.

Authors:  L A Linkins; T E Warkentin; M Pai; S Shivakumar; R A Manji; P S Wells; C Wu; I Nazi; M A Crowther
Journal:  J Thromb Haemost       Date:  2016-05-10       Impact factor: 5.824
  8 in total
  2 in total

1.  Autoimmune Heparin-Induced Thrombocytopenia: Treatment Obstacles and Challenging Length of Stay.

Authors:  Preethi Ramachandran; Fady Farag; Rewais Morcus; Vladimir Gotlieb
Journal:  Am J Case Rep       Date:  2019-03-09

2.  Rivaroxaban Treatment for Heparin-Induced Thrombocytopenia: A Case Report and a Review of the Current Experience.

Authors:  Mohamed Aon; Omar Al-Shammari
Journal:  Case Rep Hematol       Date:  2020-09-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.